Latest Beta amyloid Stories

Decision does not impact other Lilly Alzheimer's compounds in development INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the progression of Alzheimer's disease. The decision to terminate the study was due to abnormal liver biochemical tests. Clinical study investigators have...

Mount Sinai researchers find reduction in brain plaques in mice after treatment with drugs currently prescribed for other indications Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One. Led by Giulio Maria Pasinetti, MD, PhD, the Saunders Family Chair and Professor in...

NEW YORK, June 12, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer's disease. Madera has identified a series of proprietary, small molecule compounds that increase the expression of apolipoprotein E (apoE),...

Mount Sinai researchers find reduction in brain plaques in mice after treatment with drugs currently prescribed for other indications. New York, NY (PRWEB) June 12, 2013 Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer’s disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One. Led by Giulio Maria Pasinetti, MD, PhD, the Saunders...

Healthy test subjects with amyloid plaque were also found to have hypometabolism indicating a potential Alzheimer’s precursor Alzheimer’s disease has been linked in many studies to amyloid plaque buildup in the brain, but new research is finding a common thread between amyloid burden and lower energy levels, or metabolism, of neurons in certain areas of the brain associated with Alzheimer’s disease—even for people with no sign of cognitive decline. This is a new development in the...

BERLIN, BOSTON and MUMBAI, India, June 6, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent (florbetaben F18(*)) will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver from June 8-12. Additionally, Andrew Stephens, Vice President of Clinical Research and Development at Piramal Imaging will present an update and...

ZARAGOZA, Spain, June 4, 2013 /PRNewswire/ -- Alzheimer researchers in Spain have taken a step closer to finding a blood test to help in the diagnosis of Alzheimer's disease. With approximately 75% of the estimated 36 million Alzheimer's sufferers worldwide yet to receive a reliable diagnosis, the potential impact on the lives of possible sufferers, present and future, could be huge. Alzheimer's disease is a neurodegenerative disease most frequently affecting...

Scientists at the University of Liverpool and Callaghan Innovation in New Zealand have developed a new chemical approach to help harness the natural ability of complex sugars to treat Alzheimer's disease. The team used a new chemical method to produce a library of sugars, called heparan sulphates, which are known to control the formation of the proteins in the brain that cause memory loss. Heparan sulphates are found in nearly every cell of the body, and are similar to the natural...

Brett Smith for redOrbit.com - Your Universe Online While the recent failure of a potential Alzheimer’s disease treatment is bad news for patients, it serves as an important reminder of the importance of thorough pre-clinical testing of experimental drugs before beginning human trials. According to a group of University of Florida researchers, tests of the anti-cancer drug bexarotene failed to stop the formation of the amyloid brain plaques that are associated with Alzheimer’s...

Funds to Advance Research Across Key Tau Programs in Alzheimer's disease NEW YORK, May 22, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the completion of its Series B financing, which includes both issuance of new convertible preferred shares and warrants that would represent approximately $2.8M in new investments in...